Hims & Hers Health (HIMS) Following FTC Lawsuit Raises Fresh Questions About Valuation
Hims & Hers Health (HIMS) is back in focus after the Federal Trade Commission filed a lawsuit that commentators describe as a legal overhang. This is raising questions about potential costs, regulatory scrutiny, and telehealth competition.
See our latest analysis for Hims & Hers Health.
At a share price of US$27.77, Hims & Hers Health has seen short term pressure, with a 30 day share price return that declined 26.08% and year to date share price return that declined 16.88%, even though the 3 year total shareholder return of about 3.4x still reflects earlier gains. The recent drop appears tied to shifting risk perceptions after the FTC lawsuit, as investors weigh possible legal costs and regulatory uncertainty against the company’s longer term telehealth growth ambitions.
If this legal overhang has you reassessing risk and opportunity in digital healthcare, it may be worth scanning other telehealth and medical AI ideas through our screener of 41 healthcare AI stocks
For Hims & Hers Health, the sharp pullback sits between two readings. Some investors see a reset toward legal and competitive risks, while others see sentiment overshooting business realities. Which side current valuation leans toward remains the key question.
Most Popular Narrative: 83.9% Undervalued
Compared to the last close of $27.77, the most followed narrative on Hims & Hers Health points to a fair value of $173.02, which implies a wide valuation gap that some investors are watching closely.
Over the long term (10yrs), Hims & Hers has an unusually large addressable market ahead of it. The company’s growth is driven by three reinforcing dimensions:
• Expanding market size: digital healthcare adoption continues to grow globally
• Category expansion: new offerings such as hormonal health, longevity, and sleep
• International scaling: multiple geographies already in the pipeline (e.g. Brazil, Australia)
• Growth inside of the current categories
Want to see why this narrative stretches so far beyond the current $27.77 price? According to Deep_Insights, the story leans heavily on compounded revenue expansion, rising margins, and a future earnings multiple normally reserved for market leaders. Curious which growth levers and profitability assumptions sit underneath that $173.02 fair value and how they fit together over the next decade? The full narrative sets out the numbers behind that view in detail.
Result: Fair Value of $173.02 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Hims & Hers Health narrative still faces real tests, including the FTC lawsuit outcome and any slowdown in subscriber or revenue growth that undercuts long range targets.
Find out about the key risks to this Hims & Hers Health narrative.
Next Steps
With Hims & Hers Health pulled between legal worries and long range growth optimism, this is a good moment to move fast and weigh both sides for yourself. To see the balance of concerns and potential upsides that other investors are focused on, start with the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Hims & Hers Health?
If this Hims & Hers Health story has sharpened your focus on risk and reward, do not stop here. Use the screeners below to pressure test your next move.
- Target potential mispricings by scanning a focused list of 55 high quality undervalued stocks that combine strong fundamentals with attractive entry points.
- Strengthen your defensive side by reviewing 81 resilient stocks with low risk scores that aim to keep balance sheets and risk scores front and center.
- Spot fresh opportunities early by checking the screener containing 19 high quality undiscovered gems that may not yet be crowded with attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com